Zoetis is trading 4.03% up at $77.39, with the gain appearing partly supported by healthcare-sector strength despite mixed second-quarter results and reduced 2026 guidance.
- Second-quarter revenue was flat at $2.47 billion and missed estimates; adjusted EPS of $1.87 narrowly beat forecasts.
- Management cut 2026 adjusted EPS guidance to $6.15–$6.25, citing weaker U.S. companion-animal demand and competition.